| Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control. | |
| | |
MedLine Citation:
|
PMID: 20921092 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
European guidelines recommend that treating patients with hypertension to blood pressure (BP) goal is an important target for cardiovascular (CV) risk reduction. However, office BP may be a suboptimal target, given its limitations. Indeed, there is evidence that 24-h ambulatory BP monitoring (ABPM) parameters may score better in this regard, representing more accurate predictors of CV risk. In particular, mean 24-h BP and BP variability both correlate closely with hypertension end-organ damage and rate of CV events, which suggests that antihypertensive therapy should provide smooth BP control over the full 24-h dosing interval. The use of ABPM has demonstrated that fixed-dose combination therapy, comprising agents with complementary mechanisms of action, may overcome the challenge of suboptimal BP control by providing improvements in antihypertensive efficacy and tolerability throughout the 24-h period. Olmesartan/amlodipine is one of the latest combination therapies to be approved, and a number of large clinical trials have demonstrated the efficacy and tolerability of this combination in patients with mild-to-severe hypertension. Furthermore, recent ABPM studies of olmesartan/amlodipine-based treatment algorithms have shown the satisfactory 24-h antihypertensive efficacy of this fixed-dose combination. This review provides an overview of recent clinical data on the efficacy and tolerability of fixed-dose olmesartan/amlodipine combination therapy for the treatment of mild-to-severe hypertension, with a focus on sustained 24-h BP control. |
| | |
Authors:
|
Gianfranco Parati; Juan Eugenio Ochoa; Carlos Ramos; Satoshi Hoshide; Laura Lonati; Grzegorz Bilo |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Therapeutic advances in cardiovascular disease Volume: 4 ISSN: 1753-9455 ISO Abbreviation: Ther Adv Cardiovasc Dis Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-05 Completed Date: 2011-01-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101316343 Medline TA: Ther Adv Cardiovasc Dis Country: England |
Other Details:
|
Languages: eng Pagination: 301-13 Citation Subset: IM |
Affiliation:
|
Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Department of Cardiology, S. Luca Hospital, IRCCS Istituto Auxologico Italiano, via Spagnoletto, 3 20149 Milan, Italy. gianfranco.parati@unimib.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amlodipine
/
administration & dosage*,
adverse effects Angiotensin II Type 1 Receptor Blockers / administration & dosage*, adverse effects Antihypertensive Agents / administration & dosage*, adverse effects Blood Pressure / drug effects, physiology Circadian Rhythm / physiology Drug Therapy, Combination Humans Hypertension / diagnosis, drug therapy* Imidazoles / administration & dosage*, adverse effects Severity of Illness Index Tetrazoles / administration & dosage*, adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Imidazoles; 0/Tetrazoles; 0/olmesartan; 88150-42-9/Amlodipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.
Next Document: False memories and fantastic beliefs: 15 years of the DRM illusion.